1. Home
  2. MLYS vs IAC Comparison

MLYS vs IAC Comparison

Compare MLYS & IAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$30.46

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo IAC Inc.

IAC

IAC Inc.

HOLD

Current Price

$44.36

Market Cap

2.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
IAC
Founded
2019
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.7B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
MLYS
IAC
Price
$30.46
$44.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
13
Target Price
$48.67
$45.75
AVG Volume (30 Days)
1.3M
901.9K
Earning Date
05-11-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
37.43
79.97
EPS
N/A
N/A
Revenue
N/A
$4,365,235,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$0.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.59
$29.56
52 Week High
$47.65
$43.80

Technical Indicators

Market Signals
Indicator
MLYS
IAC
Relative Strength Index (RSI) 65.40 80.08
Support Level $26.85 $38.29
Resistance Level $31.09 N/A
Average True Range (ATR) 1.92 1.06
MACD 0.64 0.38
Stochastic Oscillator 89.85 98.10

Price Performance

Historical Comparison
MLYS
IAC

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About IAC IAC Inc.

IAC Inc is comprised of businesses including Angi Inc, Dotdash Meredith and Care.com, among many others ranging from early stage to established businesses. Its Dotdash Meredith segment consists of its Digital and Print businesses. Angi segment offers repairing and remodeling homes to cleaning and landscaping services. Care.com segment is a online destination for families to connect with caregivers for their children, aging parents, pets and homes and for caregivers to connect with families seeking care services. Search segment consists of a collection of websites providing general search services and information, and a Desktop business, which includes business-to-business partnership operations.

Share on Social Networks: